Pfizer
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Price above modeled range
Why: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
The range depends on model assumptions and data; it is not a prediction or investment advice.
After signing in, return here and select “Add to watchlist”. Saving companies requires a verified email address.
Market price above modeled range
Showing the EPS-based Gordon proxy you selected on the company card, using 2% growth, 2.9% terminal growth and 10.5% discount. The range varies these assumptions slightly; it is illustrative, not investment advice. Low confidence: the modelled value is far from the market price, which usually means the model does not capture this company well (for example expected growth well above its history).
Assumptions: growth 2%, discount rate 10.50%, terminal growth 2.90% (sector defaults). See a worked example.
Blended growth assumption: 2.0% (sector default 6.8%, own revenue history -6.3%, analyst revenue consensus -3.8%).
5-year outlook: relative outlook of about 5.4% a year (High confidence), anchored to a 7% market return and adjusted for how this company ranks against others. A ranking aid, not a prediction. See the full forecast.
Analyst consensus expects revenue growth of -3.8% a year; the growth assumption used is 2.0%.
Adjust assumptions
Show the recommended model instead
Why this model: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
Compare models- Recommended: Dividend discount model — USD 20.43 (-30.5%)
-
EPS-based Gordon proxy
— USD 8.42 (-71.4%)
Not used: Treats all earnings as if paid out and ignores the cash kept for reinvestment, so it overstates value for companies that retain most profit.
-
DCF (trailing free cash flow)
— USD 18.29 (-37.8%)
Not used: Free cash flow is 2.9x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
FCFF (steady state)
— USD 19.33 (-34.2%)
Not used: Free cash flow is 2.9x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
EV/EBITDA (12x)
— USD 19.68 (-33.0%)
Not used: Used only when free cash flow is far below earnings even after averaging three years; a fixed 12x multiple also ignores sector differences.
-
Fade DCF (10-year growth fade)
— USD 18.34 (-37.6%)
Not used: Free cash flow is 2.9x net income, which usually means costs such as lease payments sit outside operating cash flow, so it may be overstated.
-
EV/Sales (Rule of 40)
— USD 42.84 (+45.8%)
Not used: Used only for technology and communication companies whose cash-flow value is far below the price.
| Bear USD 6.75 | -335.7% |
| Base USD 8.42 | -249.2% |
| Bull USD 10.93 | -168.8% |
Margin = (value − price) / value, so it is measured against the value and reads lower than the upside to value, which is measured against the price. Positive means the price is below that case.
Track record: see the methodology page for how this model has performed historically, including its limits. Treat it as a screen, not a forecast.
Price history and fair value
5 years price change: -20.15% · USD 29.45 · Market data through 05 Nov 2026 ; dashed line is today’s model base value (USD 8.42). The fair value is today’s estimate, not what the model said in the past.
Saved price history is current through 05 Nov 2026; last refreshed 06 Nov 2026 18:33 (8 hours, 28 minutes ago).
08 Nov 2021Range USD 19.40 – 45.3905 Nov 2026
Latest news
Headlines provided by EODHD. Articles may mention multiple companies and are not investment recommendations.
More detail: quality, peers, price history, dividends and financials
Quality score: 74 / 100
Five equal checks on reported history: profitability, cash generation, revenue growth, balance sheet and margins. It describes business quality, not whether the price is attractive.
| Profitability | 5 of 5 years profitable | 20 / 20 |
| Cash generation | free cash flow positive in 5 of 5 years | 20 / 20 |
| Growth | revenue -10.9% a year | 4 / 20 |
| Balance sheet | net debt 3.6x EBITDA | 10 / 20 |
| Margins | EBITDA margin 21% | 20 / 20 |
Peers in Health Care
Same-sector companies with a valuation, most undervalued first. Compare the margin of safety, yield and quality score side by side.
| Company | Price | Margin of safety | P/E | P/B | Yield | Quality |
|---|---|---|---|---|---|---|
| PFE (this company) | USD 29.39 | -43.8% | 41.9 | 1.9 | 5.8% | 74 |
| CNC Centene Corporation | USD 69.74 | 45.1% | 23.6 | 1.6 | – | 72 |
| ZEAL.CO Zealand Pharma A/S | DKK 232.90 | 36.5% | 6.0 | 0.9 | – | 72 |
| CI Cigna | USD 293.59 | 30.6% | 12.1 | 1.8 | 2.1% | 70 |
| BAVA.CO Bavarian Nordic A/S | DKK 241.00 | 12.0% | 11.9 | 1.4 | – | 92 |
| CVS CVS Health | USD 83.85 | 9.7% | 9.8 | 1.3 | 3.2% | 70 |
| AMP.MI Amplifon S.p.A. | EUR 11.17 | 8.7% | 41.1 | – | 2.6% | 72 |
| ZBH Zimmer Biomet | USD 105.59 | 1.6% | 26.3 | 1.6 | 0.9% | 90 |
| GSK.L GSK plc | GBP 18.90 | -5.4% | 17.7 | 4.1 | 3.5% | 92 |
| Peer median | 14.9 | 1.6 | ||||
Dividends
Paid in the last 12 months: USD 1.72 per share · yield 5.85% at the current price.
| Year | Dividends per share |
|---|---|
| 2026 (so far) | 1.720 |
| 2025 | 1.720 |
| 2024 | 1.680 |
| 2023 | 1.640 |
| 2022 | 1.600 |
| 2021 | 1.560 |
Trailing 12-month financials
TTM through 30 Sep 2026 · quarterly EODHD data · data downloaded 07 Nov 2026 02:47
| Revenue | USD 63,624,000,000 |
|---|---|
| EBITDA | USD 13,467,000,000 |
| EBIT | USD 6,968,000,000 |
| Net income | USD 4,033,000,000 |
| Free cash flow | USD 11,787,000,000 |
| Capital expenditures | USD 2,387,000,000 |
| Debt | USD 62,671,000,000 |
| Cash | USD 14,272,000,000 |
| Working capital | USD 13,282,000,000 |
| Shares outstanding | 5,751,000,000 |
| Reported dividends per share | USD 1.7027 |